Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) dropped 1.1% during mid-day trading on Wednesday . The company traded as low as $9.57 and last traded at $9.70. Approximately 874,818 shares were traded during trading, an increase of 159% from the average daily volume of 337,931 shares. The stock had previously closed at $9.81.
Silverback Therapeutics Stock Down 1.1%
The stock’s 50-day moving average price is $8.47 and its 200-day moving average price is $9.33. The company has a market capitalization of $349.76 million, a price-to-earnings ratio of -4.01 and a beta of 0.60.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Featured Articles
- Five stocks we like better than Silverback Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
